Is Nivolumab Approved for Esophageal Cancer?
Yes, nivolumab (Opdivo) is FDA-approved for certain esophageal cancers. It targets advanced or metastatic esophageal squamous cell carcinoma (ESCC) in patients whose disease progressed after prior chemotherapy, either as monotherapy or combined with ipilimumab.[1] Approvals came in 2020 for second-line monotherapy and 2021 for first-line use with ipilimumab.[1]
How Is It Used in Esophageal Cancer Treatment?
Nivolumab, a PD-1 inhibitor, is given intravenously every 2 or 4 weeks at 240 mg or 3 mg/kg, depending on the regimen. For ESCC:
- Second-line: After platinum-based chemo plus fluoropyrimidine.
- First-line: With ipilimumab for unresectable advanced/recurrent or metastatic cases.
Clinical trials like CheckMate 648 showed improved overall survival: 13 months (nivolumab + chemo) vs. 10.7 months (chemo alone), and 12.7 months (nivolumab + ipilimumab) vs. 9.9 months.[2] It's not approved for esophageal adenocarcinoma as primary treatment but used off-label or in trials.
What Do Trial Results Show?
Key data from CheckMate 648 (phase 3, n=970):
| Regimen | Median OS (months) | HR vs. Chemo |
|---------|---------------------|--------------|
| Nivo + Chemo | 13.2 | 0.74 |
| Nivo + Ipi | 12.7 | 0.78 |
| Chemo alone | 10.7 | - |
Response rates were 24% (nivo + chemo) and 21% (nivo + ipi) vs. 13% for chemo.[2] Benefits held across PD-L1 levels, unlike some cancers. Ongoing trials test it earlier, like neoadjuvant with chemo in CheckMate 577.
What Are Common Side Effects?
Immune-related adverse events affect 40-50% of patients, including fatigue (30-40%), rash (20-30%), diarrhea (20%), and pneumonitis (5-10%). Severe cases (grade 3+) hit 20-30%, often requiring steroids or treatment holds. Esophageal-specific risks include perforation or fistula worsening, monitored closely.[1][3]
Who Makes Nivolumab and What's the Cost?
Bristol Myers Squibb manufactures Opdivo. List price per dose is ~$13,000-$18,000 (U.S.), with annual costs exceeding $150,000 depending on weight and cycles. Patient assistance programs exist; generics unavailable due to patents expiring 2033-2038.[4]
When Do Patents Expire?
Core composition patents end around 2033, with formulation and method-of-use extensions to 2038. No biosimilars approved yet; challenges from Amgen and Samsung Bioepis ongoing.[4]
[1]: FDA.gov - Opdivo Label (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.pdf)
[2]: NEJM - CheckMate 648 (https://www.nejm.org/doi/full/10.1056/NEJMoa2111380)
[3]: NCCN Guidelines - Esophageal Cancer (https://www.nccn.org/guidelines)
[4]: DrugPatentWatch.com - Opdivo Patents (https://www.drugpatentwatch.com/p/tradename/OPDIVO)